Unexpectedly, the detection rates of fibroblast growth factor receptor 2 (FGFR2) gene fusions, isocitrate dehydrogenase 1 (IDH1) mutations, and BRAF V600E were lower than those previously reported, especially in ICC (5, 6, 12, 20), leading to a lower access rate to genotype-matched therapy. The gene discussed is BRAF; the disease is intrahepatic cholangiocarcinoma.